Effect of Afsanteen (Artemisia Absinthium L.) In Treatment of Fatty Liver Disease

Effect of Afsanteen (Artemisia Absinthium L.) on liver functional indexes in patient with non alcholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190415043279N12

Enrollment

Registered

2023-02-23

Start date

2023-02-20

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcholic Fatty liver. K76.0

Interventions

Intervention 1: Intervention group: The Afsantin capsule is taken as a 1200 mg soft capsule, manufactured by Bou Ali Daru Company, twice a day for three months.The two study groups receive their respe

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with aminotransferases greater than 1.5 times the normal maximumUltrasound images with Stage 2, 3 Ultrasound images with Stage 2, 3

Exclusion criteria

Exclusion criteria: Pregnancy Lactation Alcohol consumption (more than 140 cc in men and 70 cc in women per week) Viral hepatitis Diabetic patients Patients taking drugs that affect the liver enzymes Patients taking anticoagulants People with a history of bleeding and hemostatic disorders Patients with allergies to herbs and herbal remedies

Design outcomes

Primary

Measure	Time frame
Alanine Aminotransferase (ALT). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Aspartate Aminotransferase (AST). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Alkaline Phosphatase (ALP). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Gamma glutamine transferase (GGT). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Bilirubin. Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Grade of fatty liver. Timepoint: At baseline and end of the study. Method of measurement: Sonography.;Body Mass Index (BMI). Timepoint: At baseline and end of the study. Method of measurement: by measuring height and weight using a scale and height meter.	—

Measure

Time frame

Alanine Aminotransferase (ALT). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Aspartate Aminotransferase (AST). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Alkaline Phosphatase (ALP). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Gamma glutamine transferase (GGT). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Bilirubin. Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Grade of fatty liver. Timepoint: At baseline and end of the study. Method of measurement: Sonography.;Body Mass Index (BMI). Timepoint: At baseline and end of the study. Method of measurement: by measuring height and weight using a scale and height meter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farshad Sheikhesmaeili

Sanandaj University of Medical Sciences

dr_s_smaili@yahoo.com+98 87 3366 4645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026